LY3493269 + salcaprozate sodium

This drug is a **combination of LY3493269, a synthetic peptide agonist of the gastric inhibitory polypeptide receptor (GIPR) and glucagon-like peptide 1 receptor (GLP-1R)**, with **salcaprozate sodium (SNAC), an absorption enhancer**. The pairing is developed for the **oral or oral-like delivery** of LY3493269, a molecule otherwise of poor oral bioavailability, targeting metabolic diseases such as **type 2 diabetes**. LY3493269 acts by simultaneously activating GIPR and GLP-1R, mimicking the dual agonist strategy for enhanced glycemic control and weight loss. Salcaprozate sodium facilitates the enhanced intestinal permeation and systemic absorption of the peptide component. The combination was investigated by Eli Lilly primarily for type 2 diabetes but development was discontinued after phase I due to unspecified reasons[1][3][5].

Other names

LY-3493269 + SNACLY 3493269 + SNACLY3493269 + sodium N-(8-(2-hydroxybenzoyl)amino)octanoate